Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease Undergoing Lipoprotein Apheresis
NCT05305664Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2022
- Primary completion
- Jan 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 3 trial of pelacarsen in Hyperlipoproteinemia a, sponsored by Novartis. Started Aug 2022; status: completed.
02
Drugs
pelacarsen
03
Conditions
Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT05305664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305664.